OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company’s products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepatitis; and OLX301D for subretinal fibrosis. The company has a license and collaboration agreement with Hansoh Pharmaceuticals; development collaboration with Korea Institute of Technology; and research collaboration with the University of Virginia. The company was formerly known as Biomolecular Therapeutics Inc. OliX Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Suwon-si, South Korea.
तुलना करने के लिए मीट्रिक्स | 226950 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध226950पीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −22.1x | −7.4x | −0.5x | |
PEG अनुपात | 0.27 | 0.02 | 0.00 | |
क़ीमत/बुक | 50.4x | 2.6x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 158.3x | 14.9x | 2.9x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 0.0% | 45.8% | |
उचित मूल्य अपसाइड | अनलॉक करें | 0.8% | 8.6% | अनलॉक करें |